We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aduro Biotech Inc | NASDAQ:ADRO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.595 | 14.60 | 17.00 | 0 | 01:00:00 |
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ | Preliminary Proxy Statement | |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
☐ | Definitive Proxy Statement | |
☒ | Definitive Additional Materials | |
☐ | Soliciting Material Pursuant to § 240.14a-12 |
ADURO BIOTECH, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check the appropriate box)
☒ | No fee required. | |||
☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
Title of each class of securities to which transaction applies:
|
||||
Aggregate number of securities to which transaction applies:
|
||||
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
||||
Proposed maximum aggregate value of transaction:
|
||||
Total fee paid:
|
||||
☐ | Fee paid previously with preliminary materials. | |||
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
Amount Previously Paid:
|
||||
Form, Schedule or Registration Statement No.:
|
||||
Filing Party:
|
||||
Date Filed:
|
*** Exercise Your Right to Vote ***
Important Notice Regarding the Availability of Proxy Materials for the
Stockholder Meeting to Be Held on June 8, 2017.
ADURO BIOTECH, INC. | ||
|
||
740 HEINZ AVENUE |
||
BERKELEY, CA 94710 | ||
|
||
Meeting Information
|
||
Meeting Type: | Annual Meeting | |
For holders as of: |
April 19, 2017 | |
Date: June 8, 2017 |
Time: 9:00 AM PDT | |
Location: 740 Heinz Avenue |
||
Berkeley, California 94710
|
You are receiving this communication because you hold shares in the company named above.
|
||
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
|
||
We encourage you to access and review all of the important information contained in the proxy materials before voting.
|
See the reverse side of this notice to obtain proxy materials and voting instructions.
|
Before You Vote
How to Access the Proxy Materials
Voting Items |
The Board of Directors recommends you vote FOR the following:
|
||||||||
1. |
To elect the nominees for director named below to serve as Class II directors to hold office until the 2020 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified. | |||||||
Nominees:
01) Ross Haghighat 02) Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) |
||||||||
The Board of Directors recommends you vote FOR the following proposal: |
||||||||
2. |
To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2017. |
|||||||
NOTE: To conduct any other business properly brought before the meeting or any adjournment or postponement thereof. |
||||||||
1 Year Aduro Biotech Chart |
1 Month Aduro Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions